

The Alzheimer's Disease Neuroimaging Initiative


A Public-Private Partnership

Richard J. Hodes, Director, National Institute on Aging

Alzheimer's Disease Neuroimaging Initiative (ADNI)

- Most comprehensive effort to date to find neuroimaging and other biomarkers for cognitive changes associated with MCI and AD.
- The ADNI is a \$60 million, 5-year project.
- 50 sites in the United States and Canada
- Approximately 800 older adults, ages 55 to 90, to participate in the research.
- Michael Weiner, M.D., Veterans Affairs Medical Center and UC San Francisco is principal investigator.

AD Neuroimaging Initiative Partners



Private Sector Partners Through the NIH Foundation

- Pfizer Inc
- Wyeth Research
- Eli Lilly and Company
- Merck & Co. Inc.
- GlaxoSmithKline
- AstraZeneca AB
- Novartis Pharmaceuticals Corporation
- Eisai Global Clinical Development
- Elan Corporation, plc
- Institute for the Study of Aging
- Alzheimer's Association


AD Neuroimaging Initiative

- A longitudinal, prospective, naturalistic study of normal aging, mild cognitive impairment, and early AD to evaluate neuroimaging and potential biomarkers.
- A public database, in which investigators participating and those not participating in the Initiative can use the data for analyses.

GOAL

Identify neuroimaging and biomarkers that can track the progress of MCI and AD and monitor the effectiveness of new treatments.

AD Progression




Wave of Loss in Alzheimer's Disease

Images:
Paul Thompson,
Kiralee Hayashi
and Arthur Toga

UCLA Laboratory of Neuro Imaging

Projected Number of Persons with AD using 2000 US Census Middle Series Estimates



Hebert, LE et al., Arch Neurology, 2003

More Information about Alzheimer's Disease

NIA Alzheimer's Disease Information and Referral Center
(ADEAR)

P.O. Box 8250

Silver Spring, MD 20907-8250

(800) 438-4380

adear@alzheimers.org

www.alzheimers.org